Please ensure Javascript is enabled for purposes of website accessibility

Why Aurinia Pharmaceuticals Is Soaring Today

By Brian Feroldi - Oct 16, 2019 at 11:25AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Traders are feeling bullish after management provides investors with clinical and financial updates.

What happened

Shares of Aurinia Pharmaceuticals (AUPH 4.55%), a clinical-stage biopharmaceutical company focused on rare diseases, were up 10% as of 11:05 a.m. EDT on Tuesday after management issued a press release that contained upbeat clinical and financial news.

So what

Management wanted to get three main points across to investors today.

First, its last patient study visit has occurred in its phase 3 AURORA program. This trial is studying its lead compound, voclosporin, as a hopeful treatment for lupus nephritis. Efficacy and safety data from the trial are on track to be shared with investors before the end of the year.

Second, the company has sold 2.34 million shares of common stock using its at-the-market offerings for a weighted average price of $6.40 each. This capital infusion raised about $15 million and came at a considerably higher price than yesterday's closing price of $4.67.

Third, management announced that its AURORA II study, which is a continuation of its AURORA trial, is proceeding as planned.

Drugs on top of hundred-dollar bills.

Image source: Getty Images.

Traders are reacting favorably to the plentiful good news.

Now what

2019 should be an exciting year for Aurinia's investors. If the phase 3 data from the AURORA trial looks good, the company will file for approval soon after. Success would most likely cause the share price to shoot much higher.

However, it's still hard to gauge just how well voclosporin will perform in its phase 3 trial, which is a big reason investing in clinical-stage pharma companies is so difficult. It won't be long before we know more, so my plan is to watch with enthusiasm from the sidelines.

Brian Feroldi has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Aurinia Pharmaceuticals Inc. Stock Quote
Aurinia Pharmaceuticals Inc.
$8.50 (4.55%) $0.37

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/11/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.